Your browser is no longer supported. Please, upgrade your browser.
Settings
HTBX Heat Biologics, Inc. daily Stock Chart
HTBX [NASD]
Heat Biologics, Inc.
Index- P/E- EPS (ttm)-2.54 Insider Own4.30% Shs Outstand33.79M Perf Week0.00%
Market Cap41.90M Forward P/E- EPS next Y-0.68 Insider Trans0.00% Shs Float31.26M Perf Month-8.22%
Income-22.00M PEG- EPS next Q-0.20 Inst Own16.90% Short Float3.22% Perf Quarter6.90%
Sales4.30M P/S9.74 EPS this Y27.70% Inst Trans291.53% Short Ratio1.43 Perf Half Y-33.69%
Book/sh1.07 P/B1.16 EPS next Y43.30% ROA-52.30% Target Price8.50 Perf Year-37.06%
Cash/sh0.62 P/C2.00 EPS next 5Y- ROE-85.30% 52W Range0.95 - 4.30 Perf YTD26.53%
Dividend- P/FCF- EPS past 5Y17.00% ROI-277.80% 52W High-71.49% Beta2.20
Dividend %- Quick Ratio3.40 Sales past 5Y245.00% Gross Margin- 52W Low28.79% ATR0.10
Employees19 Current Ratio3.40 Sales Q/Q260.00% Oper. Margin- RSI (14)43.04 Volatility5.44% 8.01%
OptionableNo Debt/Eq0.00 EPS Q/Q75.40% Profit Margin- Rel Volume0.43 Prev Close1.24
ShortableYes LT Debt/Eq0.00 EarningsApr 04 BMO Payout- Avg Volume705.58K Price1.23
Recom2.00 SMA20-7.67% SMA50-10.15% SMA200-28.13% Volume210,120 Change-1.12%
Jun-20-16Initiated ROTH Capital Buy
Jan-08-16Initiated Noble Financial Buy $16
May-26-15Initiated H.C. Wainwright Buy $13
Sep-18-13Initiated Aegis Capital Buy $36
Mar-21-19 07:00AM  Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy ACCESSWIRE
Mar-11-19 10:40AM  HTBX: HS-110 Interim Update Zacks Small Cap Research
Mar-05-19 09:25AM  Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai ACCESSWIRE -6.02%
Feb-28-19 05:00PM  Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium ACCESSWIRE
Feb-26-19 09:45AM  These Four Healthcare Stocks Are Heating Up On Tuesday ACCESSWIRE +17.04%
Feb-13-19 10:03AM  What Type Of Shareholder Owns Heat Biologics, Inc.s (NASDAQ:HTBX)? Simply Wall St.
Jan-14-19 02:15PM  UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial ACCESSWIRE +16.80%
08:00AM  Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial ACCESSWIRE
Jan-10-19 08:27AM  The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits Benzinga
06:30AM  Heat Biologics Provides Clinical and Business Update ACCESSWIRE
Jan-08-19 06:30AM  Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium ACCESSWIRE
Jan-04-19 07:00AM  Heat Biologics to Present at Biotech Showcase 2019 in California ACCESSWIRE
Dec-03-18 10:15AM  HTBX: Plenty of Catalysts in 2019 Zacks Small Cap Research
Nov-27-18 08:38AM  Durham company rakes in another $13.8M through public offering American City Business Journals
Nov-26-18 04:00PM  Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering ACCESSWIRE
06:00AM  Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum ACCESSWIRE
Nov-23-18 08:15AM  Detailed Research: Economic Perspectives on Whirlpool, GrafTech International, Thermon Group, White Mountains Insurance Group, Air Industries Group, and Heat Biologics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-21-18 03:21PM  Heat Biologics Takes Beating After Pricing $12 Million Stock Offering TheStreet.com -30.73%
01:37PM  Should You Be Concerned About Heat Biologics Incs (NASDAQ:HTBX) Historical Volatility? Simply Wall St.
08:04AM  The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO Benzinga
07:30AM  Heat Biologics, Inc. Prices $12,000,000 Public Offering ACCESSWIRE
Nov-20-18 03:10PM  Heat Biologics, Inc. Announces Proposed Public Offering ACCESSWIRE +9.04%
Nov-15-18 07:00AM  Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update ACCESSWIRE +8.55%
Oct-22-18 07:00AM  Heat Biologics to Present at Precision: Lung Cancer World R&D Summit ACCESSWIRE
Oct-19-18 07:00AM  Heat Biologics CEO to Participate in Panel Presentation at The Cellular ''Living Drug'' Revolution Summit in New York City ACCESSWIRE
Oct-10-18 07:00AM  Heat Biologics to Present at the 2018 BIO Investor Forum ACCESSWIRE -5.70%
Oct-04-18 07:00AM  Heat Biologics Pelican Subsidiary Provides Update on its Novel PTX-35 T-Cell Costimulator ACCESSWIRE
Sep-26-18 03:16PM  What does Heat Biologics Incs (NASDAQ:HTBX) Balance Sheet Tell Us About Its Future? Simply Wall St.
Aug-29-18 09:45AM  HTBX: Multiple Milestones on the Horizon Zacks Small Cap Research
07:00AM  Heat Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City ACCESSWIRE
Aug-15-18 04:21PM  Heat Biologics Stock Is a Worthwhile, Speculative Bet InvestorPlace
Aug-14-18 07:30AM  Heat Biologics Reports Second Quarter 2018 Results and Provides Corporate Update ACCESSWIRE
Jul-30-18 07:00AM  Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks ACCESSWIRE
Jul-16-18 09:45AM  HTBX: Heat Biologics: Making an ImPACT on Cancer Zacks Small Cap Research
Jun-29-18 07:10AM  Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space ACCESSWIRE
Jun-07-18 08:00AM  Today's Research Reports on Stocks to Watch: Axovant Sciences and Heat Biologics ACCESSWIRE
Jun-06-18 01:22PM  Is Heat Biologics Inc (NASDAQ:HTBX) Excessively Paying Its CEO? Simply Wall St. +22.13%
May-30-18 07:00AM  Heat Biologics to Present at the 2018 BIO International Convention ACCESSWIRE
May-25-18 07:15AM  Wired News - Clementia Announced Encouraging Phase-2 Part B Data Evaluating Palovarotene for FOP Treatment ACCESSWIRE
May-24-18 07:15AM  Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks ACCESSWIRE +6.80%
May-16-18 08:10AM  Todays Research Reports on Stocks to Watch: Heat Biologics, Inc. and Inovio Pharmaceuticals ACCESSWIRE +7.69%
May-15-18 07:00AM  Heat Biologics Reports First Quarter 2018 Results and Provides Corporate Update ACCESSWIRE +16.55%
May-09-18 06:51AM  Heat Biologics Inc (NASDAQ:HTBX): Risks You Need To Consider Before Buying Simply Wall St.
May-08-18 08:40AM  This Durham company is $20M richer American City Business Journals
May-07-18 05:10PM  Heat Biologics, Inc. Announces Closing of $20.7 Million Public Offering ACCESSWIRE
May-03-18 08:30AM  Heat Biologics, Inc. Prices $18,000,000 Public Offering ACCESSWIRE -48.59%
May-01-18 08:24AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +94.86%
08:10AM  Todays Research Reports on Stocks to Watch: Heat Biologics and Immunomedics ACCESSWIRE
Apr-23-18 02:57PM  Heat Bio looks to milestones, $15.5M from offering American City Business Journals
Apr-18-18 07:00AM  Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110 ACCESSWIRE
Apr-10-18 10:39AM  Who Are Heat Biologics Incs (NASDAQ:HTBX) Major Shareholders? Simply Wall St.
Mar-26-18 07:00AM  Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform ACCESSWIRE
Mar-20-18 11:57AM  On heels of adopting 'poison pill', Heat Bio recruits new scientific expertise American City Business Journals
Mar-19-18 06:00AM  Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards ACCESSWIRE -10.24%
Mar-14-18 07:00AM  Heat Biologics to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium ACCESSWIRE +7.77%
Mar-13-18 07:00AM  Heat Biologics to Present at the BIO-Europe Spring Conference, March 12-14, 2018, in Amsterdam ACCESSWIRE
Mar-12-18 08:00AM  Heat Biologics Adopts Stockholder Rights Plan ACCESSWIRE
Mar-08-18 02:59PM  Has Heat Biologics Inc (NASDAQ:HTBX) Improved Earnings Growth In Recent Times? Simply Wall St. -6.54%
Mar-02-18 05:00PM  Heat Biologics Reports Fiscal Year 2017 Financial Results ACCESSWIRE
Feb-28-18 06:00AM  Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC) ACCESSWIRE -6.67%
Feb-26-18 07:00AM  UPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer Study ACCESSWIRE +11.13%
Feb-20-18 01:00PM  Heat Biologics Receives Recommendation from Independent Data Monitoring Committee to Continue Enrollment of Phase 2 Clinical Trial for HS-110 and Nivolumab for Treatment of Non-small Cell Lung Cancer ACCESSWIRE
Feb-14-18 07:00AM  Heat Biologics Announces Poster Presentation of Interim Phase 2 Lung Cancer Clinical Data for HS-110 and Nivolumab at the 2018 Keystone Symposia Conference XI: Immunological Memory: Innate, Adaptive and Beyond ACCESSWIRE +5.81%
Feb-07-18 07:05AM  Heat Biologics CEO, Jeff Wolf, to Present at the Upcoming BIO CEO & Investor Conference in New York ACCESSWIRE
Feb-01-18 08:20AM  Todays Research Reports on Trending Tickers: Heat Biologics and ImmunoGen ACCESSWIRE
Jan-30-18 07:00AM  Heat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Results from its Phase 2 Lung Cancer Study ACCESSWIRE +8.43%
Jan-22-18 05:55PM  Heat latest Triangle biopharma to execute reverse stock split American City Business Journals -6.47%
Jan-02-18 08:39PM  Should You Be Concerned About Heat Biologics Incs (NASDAQ:HTBX) Investors? Simply Wall St.
Dec-11-17 01:58PM  ETFs with exposure to Heat Biologics, Inc. : December 11, 2017 Capital Cube -7.82%
Dec-07-17 07:00AM  Heat Biologics Receives FDA Guidance at Type C Meeting for HS-110 Clinical Trial in the Treatment of Non-small Cell Lung Cancer ACCESSWIRE
Nov-30-17 01:58PM  ETFs with exposure to Heat Biologics, Inc. : November 30, 2017 Capital Cube
11:05AM  Want To Invest In Heat Biologics Inc (HTBX)? Heres How It Performed Lately Simply Wall St.
Nov-29-17 08:44AM  Heat Biologics, Inc. :HTBX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-17-17 09:31AM  Heres Whats Behind Heat Biologics Inc (HTBX) Drop Today SmarterAnalyst -16.98%
08:00AM  Heat Biologics Prices 5,813,950 Shares for Common Stock Offering ACCESSWIRE
Nov-16-17 04:20PM  Heat Biologics Announces Proposed Public Offering of Common Stock ACCESSWIRE
Nov-14-17 03:39PM  Is It Time To Buy Heat Biologics Inc (HTBX)? Simply Wall St.
Nov-13-17 07:00AM  Heat Biologics Reports Third-quarter 2017 Results and Corporate Update ACCESSWIRE
Nov-11-17 01:08PM  Heat Biologics Presents Follow-up Data on its ComPACT(TM) T-cell Stimulating Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting ACCESSWIRE
Nov-06-17 08:00AM  Heat Biologics to Present Data on its ComPACT Technology, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting ACCESSWIRE
Oct-30-17 08:00AM  Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives Second Tranche of its $15.2 Million CPRIT Grant Award ACCESSWIRE
Oct-27-17 07:00AM  Heat Biologics Rights Offering Materials Available for Shareholders of Record ACCESSWIRE
Oct-23-17 07:00AM  Heat Biologics and its Pelican Therapeutics Subsidiary Appoint Two New Members to their Scientific Advisory Boards ACCESSWIRE
Oct-16-17 07:00AM  Heat Biologics Announces Pricing for Rights Offering to Stockholders and Participating Warrant Holders ACCESSWIRE
Oct-12-17 07:00AM  UPDATE: Heat Biologics to Present at the Upcoming BIO Investor Forum in San Francisco ACCESSWIRE -6.67%
Oct-10-17 03:59PM  Before You Buy Heat Biologics Incs (HTBX), You Should Consider This Simply Wall St.
Oct-04-17 08:00AM  Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelicans Immunotherapy Clinical Programs Business Wire +7.56%
Sep-28-17 07:00AM  Heat Biologics Announces Expected Calendar for Rights Offering ACCESSWIRE
Sep-27-17 07:00AM  Pelican Therapeutics Announces Manufacturing Agreement with KBI Biopharma to Advance Cancer-targeting Immunotherapies ACCESSWIRE
Sep-15-17 07:10AM  Heat Biologics Announces Common Stock Rights Offering in Form S-1 Filing ACCESSWIRE
Sep-14-17 07:00AM  Heat Biologics Granted 180-day Extension by NASDAQ to Regain Compliance with Listing Requirements ACCESSWIRE
Sep-13-17 08:20AM  Today's Research Reports on Stocks to Watch: Advaxis and Heat Biologics ACCESSWIRE
Sep-12-17 07:00AM  Heat Biologics Granted Type C Meeting with FDA to Discuss Registrational Pathway for HS-110 in Combination with Opdivo(R) as a Treatment for Non-Small Cell Lung Cancer ACCESSWIRE +6.54%
Sep-07-17 07:00AM  Heat Biologics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York ACCESSWIRE
Aug-14-17 07:04AM  Heat Biologics Inc. Reports Second Quarter 2017 Results ACCESSWIRE
Jul-03-17 12:15PM  Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics Accesswire
09:21AM  Durham company considers stock split to avoid delisting American City Business Journals
07:05AM  Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics Accesswire
07:00AM  Heat Biologics Appoints Damien Hallet as Vice President of CMC Development Accesswire
Jun-28-17 07:00AM  Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of $15.2 Million CPRIT Grant Award Accesswire +24.44%
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina.